A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Latest Information Update: 28 Aug 2020
At a glance
- Drugs Oteseconazole (Primary) ; Fluconazole
- Indications Vulvovaginal candidiasis
- Focus Proof of concept; Therapeutic Use
- Sponsors Viamet Pharmaceuticals
- 26 Aug 2020 According to a Mycovia Pharmaceuticals media release, results from this study was peer-reviewed and published in Clinical Infectious Diseases, a journal of the Infectious Diseases Society of America.
- 26 Aug 2020 Results presented in a Mycovia Pharmaceuticals media release.
- 20 Aug 2020 Primary endpoint (Percentage of Subjects With Therapeutic Cure at 28 Days for All Analysis Population) has not been met according to the results published in the Clinical Infectious Diseases